Novo Nordisk shares fall nearly 2% after two trial cancellations
Novo Nordisk stock traded at $46.60 Monday, down nearly 2%, after Reuters reported it stopped two ziltivekimab heart-failure trials.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.